138.76
-1.81 (-1.29%)
| Previous Close | 140.57 |
| Open | 138.99 |
| Volume | 3,630,832 |
| Avg. Volume (3M) | 805,833 |
| Market Cap | 8,427,241,472 |
| Price / Earnings (TTM) | 16.06 |
| Price / Earnings (Forward) | 4.79 |
| Price / Sales | 1.77 |
| Price / Book | 1.61 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 - 5 May 2025 |
| Profit Margin | 13.77% |
| Operating Margin (TTM) | 21.00% |
| Diluted EPS (TTM) | 8.65 |
| Quarterly Revenue Growth (YOY) | 7.50% |
| Quarterly Earnings Growth (YOY) | 103.00% |
| Total Debt/Equity (MRQ) | 150.64% |
| Current Ratio (MRQ) | 4.46 |
| Operating Cash Flow (TTM) | 1.40 B |
| Levered Free Cash Flow (TTM) | 1.43 B |
| Return on Assets (TTM) | 4.60% |
| Return on Equity (TTM) | 14.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Jazz Pharmaceuticals plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 2.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.40 |
|
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.09% |
| % Held by Institutions | 100.92% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 230.00 (Truist Securities, 65.75%) | Buy |
| Median | 179.00 (29.00%) | |
| Low | 147.00 (Piper Sandler, 5.94%) | Buy |
| Average | 184.09 (32.67%) | |
| Total | 10 Buy, 1 Hold | |
| Avg. Price @ Call | 122.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 07 May 2025 | 155.00 (11.70%) | Buy | 101.44 |
| Morgan Stanley | 07 May 2025 | 166.00 (19.63%) | Buy | 101.44 |
| 07 Mar 2025 | 183.00 (31.88%) | Buy | 138.81 | |
| Needham | 07 May 2025 | 200.00 (44.13%) | Buy | 101.44 |
| 10 Apr 2025 | 210.00 (51.34%) | Buy | 102.05 | |
| Piper Sandler | 07 May 2025 | 147.00 (5.94%) | Buy | 101.44 |
| 26 Feb 2025 | 176.00 (26.84%) | Buy | 144.17 | |
| RBC Capital | 07 May 2025 | 172.00 (23.96%) | Buy | 101.44 |
| 26 Feb 2025 | 178.00 (28.28%) | Buy | 144.17 | |
| HC Wainwright & Co. | 10 Mar 2025 | 217.00 (56.39%) | Buy | 137.45 |
| UBS | 07 Mar 2025 | 179.00 (29.00%) | Buy | 138.81 |
| Truist Securities | 06 Mar 2025 | 230.00 (65.75%) | Buy | 136.45 |
| Barclays | 27 Feb 2025 | 200.00 (44.13%) | Buy | 143.27 |
| Cantor Fitzgerald | 26 Feb 2025 | 150.00 (8.10%) | Hold | 144.17 |
| JP Morgan | 26 Feb 2025 | 209.00 (50.62%) | Buy | 144.17 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MULLIGAN SEAMUS | 103.58 | - | 1,621 | 167,903 |
| Aggregate Net Quantity | 1,621 | |||
| Aggregate Net Value ($) | 167,903 | |||
| Aggregate Avg. Buy ($) | 103.58 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MULLIGAN SEAMUS | Director | 12 May 2025 | Buy (+) | 1,621 | 103.58 | 167,903 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |